| A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. | |
| | |
MedLine Citation:
|
PMID: 12072599 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Proton pump inhibitors (PPIs) have proved to be effective in treating reflux oesophagitis. Until now, no study had compared the PPIs omeprazole Multiple Unit Pellet System (MUPS), lansoprazole and pantoprazole in patients with reflux oesophagitis. AIM: To compare omeprazole MUPS 20 mg, lansoprazole 30 mg and pantoprazole 40 mg for treatment effect in symptomatic reflux oesophagitis. METHOD: Patients with grade I-IV symptomatic reflux oesophagitis were randomized to double-blind omeprazole 20 mg once morning, lansoprazole 30 mg o.m. or pantoprazole 40 mg o.m. Patient satisfaction and symptoms were evaluated after 4 and 8 weeks. Patients not satisfied after 8 weeks were treated for another 4 weeks with omeprazole 40 mg MUPS (open). Successful treatment was followed by 3 months' maintenance treatment with omeprazole MUPS 20 mg (patients satisfied after 4 or 8 weeks) or omeprazole MUPS 40 mg (patients satisfied after 12 weeks). RESULTS: On intention-to-treat (ITT) analysis (n = 461) at 4 and 8 weeks, respectively, 84% and 87% (omeprazole MUPS), 78% and 81% (lansoprazole), and 84% and 89% (pantoprazole) were free of heartburn. Equivalence was found between omeprazole MUPS and pantoprazole (heartburn relief), but not with lansoprazole. Patient satisfaction after 4 and 8 weeks, respectively, was 79% and 89% (omeprazole MUPS), 76% and 86% (lansoprazole), and 79% and 91% (pantoprazole). Patient satisfaction was similar in all treatment groups. During maintenance, 87% in the omeprazole MUPS 20 mg group and 81% in the omeprazole MUPS 40 mg group were satisfied after 3 months. CONCLUSIONS: Omeprazole MUPS 20 mg and pantoprazole 40 mg have equivalent efficacy in the treatment of reflux oesophagitis. Based on patient satisfaction, omeprazole MUPS 20 mg, lansoprazole 30 mg and pantoprazole 40 mg are equally effective. |
| | |
Authors:
|
C J J Mulder; B D Westerveld; J M Smit; M Oudkerk Pool; M H Otten; T G Tan; A W M van Milligen de Wit; G H de Groot; |
Related Documents
:
|
16894309 - Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. 10463839 - Rheological action of aspirin on human erythrocytes. 8791969 - Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oe... 11128679 - Effect of low dose daily aspirin on serum urate levels and urinary excretion in patient... 16869819 - Dose-response in direct comparisons of different doses of aspirin, ibuprofen and parace... 10726229 - New polyethylene glycol electrolyte solution for the treatment of constipation and faec... 10909259 - Modulatory role of ginsenosides injected intrathecally or intracerebroventricularly in ... 2047109 - The leaded apron revisited: does it reduce gonadal radiation dose in dental radiology? 8049089 - Comparative analysis of electrophysiologic effect of metoprolol and disopyramide, actin... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 14 ISSN: 0954-691X ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 2002 Jun |
Date Detail:
|
Created Date: 2002-06-19 Completed Date: 2002-09-06 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 649-56 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, Rijnstate Ziekenhuis, Arnhem, The Netherlands. cjmulder@rijnstate.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles Anti-Ulcer Agents / administration & dosage* Benzimidazoles / administration & dosage* Double-Blind Method Enzyme Inhibitors / administration & dosage Esophagitis, Peptic / drug therapy* Female Humans Male Middle Aged Omeprazole / administration & dosage*, analogs & derivatives* Patient Satisfaction Proton Pumps / antagonists & inhibitors* Sulfoxides / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Benzimidazoles; 0/Enzyme Inhibitors; 0/Proton Pumps; 0/Sulfoxides; 102625-70-7/pantoprazole; 103577-45-3/lansoprazole; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia spec...
Next Document: Photodynamic therapy of human Barrett's cancer using 5-aminolaevulinic acid-induced protoporphyrin I...